Sage Therapeutics Inc. (NASDAQ:SAGE) gapped up prior to trading on Thursday . The stock had previously closed at $43.15, but opened at $43.20. Sage Therapeutics shares last traded at $43.90, with a volume of 265,001 shares changing hands.

A number of equities research analysts have recently issued reports on the stock. William Blair restated an “outperform” rating and issued a $75.00 target price on shares of Sage Therapeutics in a research note on Friday, July 15th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $71.00 price objective on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Cowen and Company reiterated a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Chardan Capital reiterated a “sell” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $66.18.

The stock’s market cap is $1.39 billion. The company’s 50 day moving average is $33.59 and its 200 day moving average is $34.67.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.01. Equities research analysts forecast that Sage Therapeutics Inc. will post ($4.34) EPS for the current fiscal year.

In other Sage Therapeutics news, Director Kevin P. Starr sold 850,000 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $31.25, for a total value of $26,562,500.00. Following the sale, the director now directly owns 65,227 shares in the company, valued at approximately $2,038,343.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kimi Iguchi sold 5,000 shares of the firm’s stock in a transaction on Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total transaction of $247,750.00. Following the completion of the sale, the chief financial officer now owns 83,739 shares in the company, valued at $4,149,267.45. The disclosure for this sale can be found here.

A number of hedge funds recently bought and sold shares of SAGE. California State Teachers Retirement System raised its stake in Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 400 shares in the last quarter. Nationwide Fund Advisors raised its stake in shares of Sage Therapeutics by 9.4% in the fourth quarter. Nationwide Fund Advisors now owns 21,143 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 1,816 shares during the period. ProShare Advisors LLC raised its stake in shares of Sage Therapeutics by 8.2% in the fourth quarter. ProShare Advisors LLC now owns 25,219 shares of the biopharmaceutical company’s stock valued at $1,470,000 after buying an additional 1,919 shares during the period. Marshall Wace LLP acquired a new stake in shares of Sage Therapeutics during the fourth quarter valued at $1,870,000. Finally, GAM Holding AG raised its stake in shares of Sage Therapeutics by 74.1% in the fourth quarter. GAM Holding AG now owns 79,400 shares of the biopharmaceutical company’s stock valued at $4,629,000 after buying an additional 33,800 shares during the period.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.